Hidden Antivirals Discovered in a Plant-Derived Supplement

Why It Matters

The discovery reveals untapped antiviral agents in widely used botanical supplements, offering a fast‑track lead for pandemic‑ready therapeutics and highlighting the need for deeper chemical profiling of natural products.

Key Takeaways

• Trace dicitriosides show nanomolar antiviral activity
• Potency 25× higher than 90% isoquercitrin mixture
• Activity found in <1% of original supplement
• Discovery highlights variability among plant‑derived supplements
• Researchers aim to identify source plants for drug development

Pulse Analysis

The breakthrough emerged from a two‑year collaboration between the University of Illinois Chicago and the Montreal Clinical Research Institute, where scientists used counter‑current chromatography and a seven‑meter Sephadex column to strip isoquercitrin from a commercial supplement. By tracking antiviral activity through successive fractions, they pinpointed dicitriosides—rare triterpenoid molecules present at sub‑percent levels—as the true bioactive agents. In vitro assays demonstrated nanomolar inhibition of Ebola, Zika and SARS‑CoV‑2, with potency roughly 25 times greater than the crude 90 % mixture, positioning these compounds as compelling candidates for antiviral drug pipelines.

Beyond the laboratory, the study raises a red flag for the nutraceutical industry, where plant extracts are often sold as standardized isolates despite inherent compositional diversity. The fact that a less‑pure supplement harbored powerful antivirals while a higher‑purity counterpart did not illustrates how minor, undocumented constituents can dramatically alter efficacy and safety. Regulators and manufacturers may need to adopt more rigorous phytochemical fingerprinting and batch‑to‑batch consistency checks to ensure that consumers receive products with predictable biological profiles.

Looking ahead, the research teams are mapping the botanical origins of dicitriosides, a step that could enable scalable extraction or synthetic analog development. If preclinical models confirm in vivo activity and acceptable toxicity, these molecules could accelerate the pipeline for broad‑spectrum antivirals, a strategic asset in the face of emerging viral threats. Their discovery also revitalizes interest in natural‑product libraries as reservoirs of novel therapeutics, reinforcing the value of meticulous fractionation and bioassay‑guided discovery in modern drug development.